Chemomab Ltd. is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.
Chemomab is making great strides with its novel anti-CCL24 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.
CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.
Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver, skin and lung fibrosis.